Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:41 2023-12-08 am EST			5-day change	1st Jan Change
84.72 ^CHF	+0.56%		-0.77%	+1.35%

Dec. 08	Novartis welcomes "significant milestone" for Kisqali	AN
Dec. 08	Novartis Says Latest Kisqali Trial Analysis Reinforces Over 25% Reduction in Risk of Breast Cancer Recurrence	MT

NOVARTIS AG : Gets a Buy rating from Deutsche Bank

July 10, 2023 at 07:33 am EDT

Already positive, the research from Deutsche Bank and its analyst Emmanuel Papadakis still consider the stock as a Buy opportunity. The target price is still set at CHF 110.

Latest news about Novartis AG

Novartis welcomes "significant milestone" for Kisqali	Dec. 08	AN
Novartis Says Latest Kisqali Trial Analysis Reinforces Over 25% Reduction in Risk of Breast Cancer Recurrence	Dec. 08	MT
Novartis: positive results in early breast cancer	Dec. 08	CF
Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer	Dec. 08	CI
New entries in MarketScreener's Europe portfolio	Dec. 08
Daiichi Sankyo Subsidiary, Plexxikon, Wins Patent Lawsuit; Novartis to Pay $182 Million Settlement	Dec. 07	MT
European Midday Briefing : Disappointing Data Weigh on Sentiment	Dec. 07	DJ
Swiss Market Index Extends Gains as Dovish Narrative Lifts Sentiment	Dec. 06	MT
Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials	Dec. 06	DJ
Novartis Says FDA Approved Oral Monotherapy for Blood Disorder	Dec. 06	MT
Novartis: FDA approval in HPN	Dec. 06	CF
Novartis Receives FDA Approval for Fabhalta Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH	Dec. 06	CI
Novartis Wins First-in-Class US FDA Nod for Rare Blood Disorder Drug	Dec. 05	MT
Merck KGaA suffers major blow as MS drug fails in late-stage trials	Dec. 05	RE
Merck KGaA says MS drug fails in late-stage trials	Dec. 05	RE
Anything is possible	Dec. 05
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	Dec. 05	MT
NOVARTIS AG : JP Morgan remains Neutral	Dec. 05	ZD
Blackstone explores sale of Anthos Therapeutics -sources	Dec. 04	RE
Blackstone Mulling Potential Sale of Blood-Thinner Developer Anthos	Dec. 04	MT
Blackstone explores sale of Anthos Therapeutics -sources	Dec. 04	RE
NOVARTIS AG : Deutsche Bank gives a Buy rating	Nov. 30	ZD
NOVARTIS : Oddo BHF confirms its recommendation after R&D day	Nov. 29	CF
NOVARTIS AG : Sell rating from Barclays	Nov. 29	ZD
Novartis' Kymriah, Other CAR-T Cancer Therapies Under US Investigation Over Alleged Safety Issues	Nov. 29	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (18.3%; Sandoz). Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).

Sector

Pharmaceuticals

Calendar

2024-01-07 - JPMorgan Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : Healthy Q3; guidance upgraded ‘again’

October 24, 2023 at 10:00 am EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

96.17USD

Average target price

105.75USD

Spread / Average Target

+9.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+1.35%	198 B $
ELI LILLY AND COMPANY	+63.47%	529 B $
NOVO NORDISK A/S	+42.56%	430 B $
JOHNSON & JOHNSON	-12.58%	374 B $
MERCK & CO., INC.	-6.49%	263 B $
ABBVIE INC.	-7.63%	261 B $
ASTRAZENECA PLC	-9.77%	197 B $
PFIZER, INC.	-43.83%	162 B $
AMGEN INC.	+2.47%	145 B $
SANOFI	-4.13%	115 B $